New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
08:26 EDTMNKD, PFEMannKind future riding on Afrezza prospects, LA Times
The future of MannKind (MNKD) and the fate of its investors is riding on an inhaled form of insulin powder, which Pfizer (PFE) tried in 2006 to market but gave up on after sales failed to meet expectations, said The Los Angeles Times. MannKind hopes to get federal approval for its version, Afrezza, by spring of 2014, the report noted. Reference Link
News For MNKD;PFE From The Last 14 Days
Check below for free stories on MNKD;PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 21, 2014
07:06 EDTPFEPfizer bid for AstraZeneca 'looks highly probable,' says Citigroup
Citigroup believes Pfizer's (PFE) reported takeover interest in AstraZeneca (AZN) "looks highly probable." Citi thinks a deal would fit Pfizer's strategic goals for immunotherapy and autoimmune disease and would also be financially attractive. The firm expects Pfizer to "aggressively" approach AstraZeneca a second time.
06:47 EDTPFEAstraZeneca volatility elevated, said to have been approached by Pfizer – report
AstraZeneca (AZN) implied volatility is expected is to move on Pfizer (PFE) is said to have approached to propose a $101B takeover, says the Sunday Times. Overall option implied volatility of 20 is above its 26-week average of 18 according to Track Data, suggesting large price movement.
06:40 EDTPFEPfizer volatility flat said to be considering bid for AstraZeneca – report
Subscribe for More Information
06:14 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 20, 2014
20:37 EDTPFEPfizer said to be considering GBP60B bid for AstraZeneca, Sunday Times says
Drug giant Pfizer (PFE) is said to have approached AstraZeneca (AZN) to propose a GBP60B takeover of the U.K company, says the Sunday Times. Informal discussions have recently taken place, say sources, but AstraZeneca is believed to be resisting Pfizer’s approach, added the Sunday Times. Reference Link
16:45 EDTPFEBiogen hemophilia drug Alprolix priced similar to older treatments, Reuters says
Subscribe for More Information
April 17, 2014
08:38 EDTPFETeva settles patent ligitigation with Pfizer on Celebrex
Teva (TEVA) announced that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer (PFE) related to Teva’s generic version of Celebrex 50, 100, 200 and 400 mg capsules in the United States. Under the terms of the settlement, Teva may launch its generic versions in December 2014 or earlier under certain circumstances. Teva has received tentative approval from the U.S. Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100, 200 and 400 mg capsules. Sales of Celebrex were $2.2B in the U.S. according to IMS data as of December, 2013.
03:54 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Stocks with implied volatility below IV index mean; Questcor (QCOR) 47, MannKind (MNKD) 82 according to iVolatility.
April 16, 2014
06:23 EDTMNKD Stocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 15, 2014
08:04 EDTPFEWuXi PharmaTech names Steve Yang as COO and Executive VP
Subscribe for More Information
06:32 EDTPFEPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
06:04 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 14, 2014
09:05 EDTPFEGlycoMimetics presents GMI-1070 data
Subscribe for More Information
05:54 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Stocks with implied volatility below IV index mean; Questcor (QCOR) 44, MannKind (MNKD) 83 according to iVolatility.
April 11, 2014
10:46 EDTMNKDOptions with decreasing implied volatility: MNKD QCOR NQ WWE BBBY
07:19 EDTPFEAcura Pharma to host conference call
Subscribe for More Information
06:04 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 10, 2014
12:29 EDTMNKDMannKind retreats after potential rival starts IPO process
Shares of drug maker MannKind (MNKD) are falling after a potential competitor, Dance Biopharm, sought to launch an initial public offering. WHAT'S NEW: Dance Biopharm filed papers with the SEC to raise $75M through an IPO last night. Like Mannkind, Dance has developed an inhaled insulin product that is supposed to treat diabetes. Dance's lead product, Dance 501, is designed to deliver liquid insulin through a small, handheld electronic inhaler, Dance stated in its IPO application. The company plans to launch a Phase III trial of the product in early 2015 and eventually seek regulatory approval of the product in the EU, U.S., and China. MannKind's AFREZZA, which is designed to deliver insulin through an inhaler, is currently under review for approval by the FDA. PRICE ACTION: In early afternoon trading, MannKind sank 30c, or 4.3%, to $6.70.
11:03 EDTMNKDOptions with decreasing implied volatility: MNKD QCOR MU KMX
06:17 EDTPFEAcura Pharma announces return of product rights from Pfizer
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use